01—Abstract
Summary
Summary of the 8-K filed January 12, 2026. Cited figures are marked; the original filing is the authoritative source.
Guardant Health (GH) furnished preliminary, unaudited results for Q4 and full year 2025 via an 8-K filed January 12, 2026, ahead of its J.P.
Morgan Healthcare Conference presentation. Fourth-quarter revenue was approximately $280 milliona, up 39% year over year, driven by strong Oncology and Screening volume. Full-year 2025 revenue was approximately $981 million, up 33%, with growth accelerating through the year.
Oncology tests reached roughly 276,000 for the year (up 34%), and Shield screening tests reached roughly 87,000, versus about 6,400 in Q4 2024, reflecting rapid adoption of the blood-based colorectal cancer screening test. The headline growth is offset by cash consumption. Preliminary free cash flow was approximately negative $54 millionb in Q4 2025 and negative $233 million for the full year, compared with negative $275 million in 2024, so cash burn improved year over year despite the revenue ramp.
Cash, cash equivalents, restricted cash, and marketable debt securities totaled approximately $1.3 billionc at December 31, 2025, providing a substantial liquidity cushion. Investors should treat these figures with caution.
The company explicitly states that its financial statements are not yet complete, that the numbers are preliminary and unaudited, and that the independent auditors may identify items that cause final results to differ materially. Audited fourth-quarter and full-year results are expected during the February 2026 earnings call, and that release will be the reliable basis for valuation.
02—Key points
Key Highlights
- Q4 2025 preliminary revenue of approximately $280 million, up 39% year over year, the company's strongest growth quarter cited in the release
- Full-year 2025 preliminary revenue of approximately $981 million, up 33%, with management describing revenue growth as accelerating
- Oncology test volume of approximately 79,000 in Q4 (up 38%) and approximately 276,000 for the full year (up 34%)
- Shield screening tests of approximately 38,000 in Q4 versus 6,400 a year earlier, and approximately 87,000 for full-year 2025; nearly 100,000 patients screened since FDA approval per management
- Free cash flow of approximately negative $54 million in Q4 and negative $233 million for full-year 2025, an improvement from negative $275 million in 2024
- Cash, cash equivalents, restricted cash, and marketable debt securities of approximately $1.3 billion as of December 31, 2025
- Preliminary figures are unaudited and subject to change; audited Q4 and full-year results are expected at the February 2026 earnings call
03—Questions
Frequently Asked Questions
Why did Guardant release preliminary results before its audited financials were complete?
The company disclosed the figures in connection with its J.P. Morgan Healthcare Conference presentation on January 12, 2026. The release states that year-end close and review procedures are still in progress, so the numbers are preliminary and unaudited. The company did not specify a precise reason for releasing them early, but the timing aligns with a major investor event.
How much could the preliminary results change when audited?
The filing does not quantify potential adjustments. It warns that final results may differ materially from the estimates because the independent registered public accountants may identify items during the audit. Investors should wait for the audited results in February 2026 before relying on these figures for valuation.
What is driving the Shield growth, and how significant is it?
Shield, the company's blood-based colorectal cancer screening test, went from about 6,400 tests in Q4 2024 to about 38,000 in Q4 2025, and reached roughly 87,000 tests for the full year. Management describes it as one of the most successful diagnostic launches to date and notes that multi-cancer detection findings have been added to the platform, which could support future clinical and commercial value.
Is Guardant's cash position sufficient given continued negative free cash flow?
Based on the preliminary figures, Guardant had about $1.3 billion in cash, equivalents, restricted cash, and marketable debt securities at year-end 2025, against full-year negative free cash flow of about $233 million. That implies a sizable cushion at the current burn rate, though the filing does not provide guidance on future cash needs, and the balance sheet should be reviewed in the audited report.
04—Continue